GSK to present a keynote address on Tiered Pricing at European Pharmaceutical Pricing and Reimbursement

This year's conference, taking place on 5-6 October 2015 in London, will feature an array of case studies from major global pharmaceutical companies including MSD, Sanofi and GSK. End Quote

(1888PressRelease) August 22, 2015 - Recent advances in the sophistication of HTA analysis and modelling, flexible pay for performance models, risk-sharing and value-based pricing schemes have become increasingly important to mitigate payer risk and allocate financial resources to the areas of pressing need. Savings and outcome improvements can also be found through finding efficiency gains at the healthcare delivery level, providing the right incentives for prescribers and improving patient adherence.

Against this backdrop, SMi's 21st annual European Pharmaceutical Pricing & Reimbursement conference will provide the ideal platform for payers and other decision makers from both public and private organisations, to benchmark with peers internationally and provide pharmaceutical companies with an invaluable insight into the decision making processes and approaches of these vital stakeholders. The two-day conference programme will help further your understanding and enable you to develop best practice approaches to such complex market access & pricing challenges, with the ultimate goal of encouraging innovation and improving patient access to novel and powerful medications though case studies presented by GSK, Sanofi, MSD and more who will be presenting at the two-day conference.

Unique perspectives will also be provided on:
• Case studies assessing of the impact Biosimilars and Orphan Drugs on the the market with MSD and Quintiles
• Tiered pricing options with a case study from GSK
• Case studies in Reforms with Sanofi sharing their perspective
• Evaluating new models for European reimbursement
• Health Technology Assessment policies
• Changes in UK P&R policy following the UK elections with presentations from industry bodies such as EMIG and the ABPI

Furthermore, SMi is pleased to announce that GSK's Head of Emerging Markets Pricing, Ken Walsh, will be leading a keynote address on Tiered Pricing at SMi's European Pharmaceutical Pricing & Reimbursement conference on Day 2. He will be sharing his insight on the following topic areas:
• Increasing market access through the development of Tiered Pricing
• Understanding new mechanisms to accessing a challenging market
• Developing socioeconomic methodologies to increase medication access

Speaker Panel includes:
• Leslie Galloway, Chairman, Ethical Medicines Industry Group
• Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs
• Janice Haigh, Practice Leader Market Access, Quintiles
• David Watson, Director of Pricing & Reimbursement, ABPI
• Ken Walsh, Head of Emerging Markets Pricing, GSK
• Toros Sahin, Head of Market Access & Health Economics, Sanofi Turkey
• Alexander Roediger, Director European Union Affairs, MSD
• Leyla Hannbeck, Head of Pharmacy, National Pharmaceutical Association Ltd
• Eric Low, CEO, Myeloma UK
• Maggie Dolan, Regional Pharmacy Procurement Specialist, NHS Commercial Solutions

To view the full speaker line-up and conference programme, visit http://www.pharmaceuticalpricing.co.uk/1888pressrelease

###

space

Other Related Press Releases